Resmed Acquires Noctrix Health to Enter Restless Legs Syndrome Market
The acquisition adds the FDA-cleared, non-pharmacologic Nidra TOMAC therapy to Resmed’s portfolio, expanding its reach into the treatment of restless legs syndrome.
The acquisition adds the FDA-cleared, non-pharmacologic Nidra TOMAC therapy to Resmed’s portfolio, expanding its reach into the treatment of restless legs syndrome.
The updated guideline emphasizes iron evaluation and supplementation while recommending against the use of dopamine agonists due to risks of symptom worsening.
The 2022 CDC Opioid Prescribing Guidelines released on November 3, 2022, replaced earlier guidelines that had led to confusion, misinterpretation, and faulty application by medical providers, according to a statement from the RLS Foundation.
Read MoreThe International Restless Legs Syndrome Study Group publishes a new guideline on construct validity of rodent models of RLS.
Read MoreA new study found Pycnogenol French maritime pine bark extract to significantly relieve and prevent symptoms associated with restless legs syndrome.
Read MoreIn ODYSSEY II, 2,745 people with confirmed RLS completed a survey about RLS diagnosis and severity, associated medical conditions, treatments, and medical care.
Read MoreTwenty percent of restless legs syndrome patients are already on higher-than-recommended doses of dopamine agonists, says John Winkelman, MD, PhD.
Read MoreThe acquisition of APIRx will significantly strengthen Incannex’s position with regard to cannabinoid and psychedelic treatment development.
Read MoreBen Wipper discusses the study “Restless legs syndrome severity in the National RLS Opioid Registry during the COVID-19 pandemic.”
Read MoreAzurity Pharmaceuticals Inc has acquired Arbor Pharmaceuticals Inc, marketers of the restless legs syndrome drug Horizant.
Read MoreRelaxis, a vibratory counterstimulation device for RLS patients that was FDA cleared in 2014, is no longer filling new prescriptions.
Read More